June 16, 2025 04:48 AM EDTUpdated 06:39 AM
R&D
Cell/Gene Tx

Gilead, Ar­cel­lx con­tin­ue to spot­light safe­ty of mul­ti­ple myelo­ma cell ther­a­py

Lei Lei Wu

News Reporter

Gilead and Ar­cel­lx re­port­ed that their mul­ti­ple myelo­ma CAR-T ther­a­py con­tin­ued to show po­ten­tial­ly bet­ter safe­ty than Leg­end Biotech and John­son & John­son’s Carvyk­ti, with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

What's com­ing in five years? FDA chief points to uni­ver­sal flu vac­cine, new ap­proval path­way

Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

For­mer CEO Anne Wo­j­ci­c­ki wins bid for 23andMe

Roche moves ahead with Phase 3 Parkin­son’s study de­spite mixed tri­al re­sults

sponsored

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

A service from the Financial Times